During the last session, Theravance Biopharma Inc. (NASDAQ:TBPH)’s traded shares were 0.47 million, with the beta value of the company hitting 0.79. At the end of the trading day, the stock’s price was $8.45, reflecting an intraday loss of 0.00% or $0.0. The 52-week high for the TBPH share is $22.74, that puts it down -169.11 from that peak though still a striking 27.81% gain since the share price plummeted to a 52-week low of $6.10. The company’s market capitalization is $595.98M, and the average intraday trading volume over the past 10 days was 0.5 million shares, and the average trade volume was 1.34 million shares over the past three months.
Theravance Biopharma Inc. (TBPH) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 2.60. TBPH has a Sell rating from 1 analyst(s) out of 9 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.78.
Theravance Biopharma Inc. (NASDAQ:TBPH) trade information
Theravance Biopharma Inc. (TBPH) registered a 0.00% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet 0.00% in intraday trading to $8.45 this Wednesday, 11/24/21, hitting a weekly high. The stock’s 5-day price performance is 6.69%, and it has moved by 7.64% in 30 days. Based on these gigs, the overall price performance for the year is -49.00%. The short interest in Theravance Biopharma Inc. (NASDAQ:TBPH) is 2.61 million shares and it means that shorts have 7.11 day(s) to cover.
The consensus price target of analysts on Wall Street is $10.13, which implies an increase of 16.58% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7.00 and $14.00 respectively. As a result, TBPH is trading at a discount of -65.68% off the target high and 17.16% off the low.
Theravance Biopharma Inc. (TBPH) estimates and forecasts
Statistics show that Theravance Biopharma Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Theravance Biopharma Inc. (TBPH) shares have gone down -51.46% during the last six months, with a year-to-date growth rate more than the industry average at 36.32% against 17.10. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 32.80% this quarter and then jump 13.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -13.10% compared to the previous financial year.
Revenue for the current quarter is expected to be $16.1 million as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to $20.03 million by the end of Dec 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $18.57 million and $18.73 million respectively. In this case, analysts expect current quarter sales to shrink by -13.30% and then jump by 6.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 3.50%. While earnings are projected to return -4.90% in 2021.
Theravance Biopharma Inc. is due to release its next quarterly earnings on May 04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Theravance Biopharma Inc. (NASDAQ:TBPH)’s Major holders
Theravance Biopharma Inc. insiders own 16.74% of total outstanding shares while institutional holders control 84.58%, with the float percentage being 101.59%. FMR, LLC is the largest shareholder of the company, while 183 institutions own stock in it. As of Jun 29, 2021, the company held over 10.79 million shares (or 14.69% of all shares), a total value of $156.7 million in shares.
The next largest institutional holding, with 9.91 million shares, is of Baupost Group, Inc,.(The) LLC’s that is approximately 13.49% of outstanding shares. At the market price on Jun 29, 2021, these shares were valued at $143.9 million.
Also, the Mutual Funds coming in first place with the largest holdings of Theravance Biopharma Inc. (TBPH) shares are Fidelity Growth Company Fund and Vanguard Explorer Fund, Inc. Data provided on Jun 29, 2021 indicates that Fidelity Growth Company Fund owns about 2.08 million shares. This amounts to just over 2.83 percent of the company’s overall shares, with a $30.18 million market value. The same data shows that the other fund manager holds slightly less at 1.85 million, or about 2.52% of the stock, which is worth about $36.51 million.